NASDAQ:ADMP

Adamis Pharmaceuticals Stock Forecast, Price & News

$0.82
-0.03 (-3.70 %)
(As of 04/13/2021 03:24 PM ET)
Add
Compare
Today's Range
$0.76
Now: $0.82
$0.84
50-Day Range
$0.88
MA: $1.01
$1.38
52-Week Range
$0.32
Now: $0.82
$2.34
Volume139,896 shs
Average Volume18.09 million shs
Market Capitalization$109.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Adamis Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMP
CUSIPN/A
Phone858-997-2400
Employees131
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.11 million
Book Value$0.58 per share

Profitability

Net Income$-29,310,000.00
Net Margins-188.31%

Miscellaneous

Market Cap$109.71 million
Next Earnings Date5/17/2021 (Estimated)
OptionableOptionable

Headlines

Adamis Pharmaceuticals Provides an Update on ZIMHI™
April 12, 2021 |  finance.yahoo.com
Why Novavax, Adamis Pharma And More Are Moving Today
January 29, 2021 |  markets.businessinsider.com
Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar
January 21, 2021 |  finance.yahoo.com
Adamis Soars After Submitting Covid Drug to FDA
January 20, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

771st out of 2,016 stocks

Pharmaceutical Preparations Industry

374th out of 771 stocks

Analyst Opinion: 3.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$0.82
-0.03 (-3.70 %)
(As of 04/13/2021 03:24 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

Is Adamis Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Adamis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMP, but not buy additional shares or sell existing shares.
View analyst ratings for Adamis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Adamis Pharmaceuticals?

Wall Street analysts have given Adamis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adamis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Adamis Pharmaceuticals?

Adamis Pharmaceuticals saw a drop in short interest in the month of February. As of February 26th, there was short interest totaling 3,240,000 shares, a drop of 21.5% from the February 11th total of 4,130,000 shares. Based on an average daily volume of 18,670,000 shares, the short-interest ratio is presently 0.2 days.
View Adamis Pharmaceuticals' Short Interest
.

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 17th 2021.
View our earnings forecast for Adamis Pharmaceuticals
.

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) announced its quarterly earnings data on Saturday, November, 14th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.05. The specialty pharmaceutical company earned $4.30 million during the quarter, compared to analyst estimates of $8.15 million. Adamis Pharmaceuticals had a negative net margin of 188.31% and a negative trailing twelve-month return on equity of 99.57%.
View Adamis Pharmaceuticals' earnings history
.

How has Adamis Pharmaceuticals' stock price been impacted by COVID-19?

Adamis Pharmaceuticals' stock was trading at $0.4029 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ADMP shares have increased by 91.4% and is now trading at $0.7710.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ADMP?

3 analysts have issued 1 year price objectives for Adamis Pharmaceuticals' stock. Their forecasts range from $1.00 to $1.50. On average, they expect Adamis Pharmaceuticals' share price to reach $1.25 in the next year. This suggests a possible upside of 62.1% from the stock's current price.
View analysts' price targets for Adamis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the following people:
  • Mr. Richard C. Williams, Independent Chairman & Consultant (Age 77, Pay $128k)
  • Dr. Dennis J. Carlo, Pres, CEO & Director (Age 78, Pay $697.57k)
  • Mr. Robert O. Hopkins, Sr. VP of Fin., CFO & Sec. (Age 61, Pay $455.16k)
  • Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 51)
  • Dr. Ronald B. Moss, Chief Medical Officer (Age 60, Pay $481.36k)
  • Mr. Robert B. Rothermel, Consultant (Age 77, Pay $41.81k)
  • Mr. Howard C. Birndorf, Independent Director & Consultant (Age 70, Pay $47.82k)
  • Ms. Roshawn A. Blunt, Independent Director & Consultant (Age 46, Pay $47.82k)
  • Ms. Karen K. Daniels, VP of Operations (Age 68)
  • Mr. Mark Flather, Sr. Director of Investor Relations & Corp. Communications

Who are some of Adamis Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $0.77.

How much money does Adamis Pharmaceuticals make?

Adamis Pharmaceuticals has a market capitalization of $103.47 million and generates $22.11 million in revenue each year. The specialty pharmaceutical company earns $-29,310,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Adamis Pharmaceuticals have?

Adamis Pharmaceuticals employs 131 workers across the globe.

What is Adamis Pharmaceuticals' official website?

The official website for Adamis Pharmaceuticals is www.adamispharmaceuticals.com.

Where are Adamis Pharmaceuticals' headquarters?

Adamis Pharmaceuticals is headquartered at 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.